Serviço de Medicina Intensiva, Hospitais da Universidade de Coimbra, Praceta Professor Mota Pinto 3000-075, Coimbra, Portugal.
Int J Antimicrob Agents. 2012 May;39(5):420-3. doi: 10.1016/j.ijantimicag.2011.12.011. Epub 2012 Mar 3.
The aim of this study was to evaluate the effect of augmented renal clearance (ARC) on vancomycin serum concentrations in critically ill patients. This prospective, single-centre, observational, cohort study included 93 consecutive, critically ill septic patients who started treatment that included vancomycin by continuous infusion, admitted over a 2-year period (March 2006 to February 2008). ARC was defined as 24-h creatinine clearance (CL(Cr))>130 mL/min/1.73 m(2). Two groups were analysed: Group A, 56 patients with a CL(Cr)≤130 mL/min/1.73 m(2); and Group B, 37 patients with a CL(Cr)>130 mL/min/1.73 m(2). Vancomycin therapeutic levels were assessed on the first 3 days of treatment (D(1), D(2) and D(3)). Serum vancomycin levels on D(1), D(2) and D(3), respectively, were 13.1, 16.6 and 18.6 μmol/L for Group A and 9.7, 11.7 and 13.8 μmol/L for Group B (P<0.05 per day). The correlation between CL(Cr) and serum vancomycin on D(1) was -0.57 (P<0.001). ARC was strongly associated with subtherapeutic vancomycin serum concentrations on the first 3 days of treatment.
本研究旨在评估急性肾损伤(ARC)对重症患者万古霉素血药浓度的影响。这是一项前瞻性、单中心、观察性、队列研究,纳入了 93 例连续的、重症脓毒症患者,这些患者在 2 年期间(2006 年 3 月至 2008 年 2 月)接受了连续输注万古霉素的治疗。ARC 定义为 24 小时肌酐清除率(CL(Cr))>130 mL/min/1.73 m(2)。将患者分为两组:A 组,56 例 CL(Cr)≤130 mL/min/1.73 m(2);B 组,37 例 CL(Cr)>130 mL/min/1.73 m(2)。在治疗的第 1、2、3 天(D1、D2 和 D3)评估万古霉素的治疗水平。A 组患者在 D1、D2 和 D3 的血清万古霉素水平分别为 13.1、16.6 和 18.6 μmol/L,B 组患者的血清万古霉素水平分别为 9.7、11.7 和 13.8 μmol/L(P<0.05/天)。在 D1 时,CL(Cr)与血清万古霉素之间的相关性为-0.57(P<0.001)。ARC 与治疗的前 3 天内出现的治疗性万古霉素血清浓度较低密切相关。